CO2021013279A2 - Anticuerpos de cadena pesada que se unen al psma - Google Patents

Anticuerpos de cadena pesada que se unen al psma

Info

Publication number
CO2021013279A2
CO2021013279A2 CONC2021/0013279A CO2021013279A CO2021013279A2 CO 2021013279 A2 CO2021013279 A2 CO 2021013279A2 CO 2021013279 A CO2021013279 A CO 2021013279A CO 2021013279 A2 CO2021013279 A2 CO 2021013279A2
Authority
CO
Colombia
Prior art keywords
psma
heavy chain
bind
chain antibodies
antibodies
Prior art date
Application number
CONC2021/0013279A
Other languages
English (en)
Inventor
Schooten Wim Van
Starlynn Clarke
Kevin Dang
Ben Buelow
Original Assignee
Teneobio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teneobio Inc filed Critical Teneobio Inc
Publication of CO2021013279A2 publication Critical patent/CO2021013279A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se describen anticuerpos de cadena pesada anti-PSMA (por ejemplo, UniAbsTM), junto con métodos para preparar dichos anticuerpos, composiciones, incluidas composiciones farmacéuticas, que comprenden dichos anticuerpos, y su uso para tratar trastornos caracterizados por la expresión del PSMA.
CONC2021/0013279A 2019-04-05 2021-10-04 Anticuerpos de cadena pesada que se unen al psma CO2021013279A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962830130P 2019-04-05 2019-04-05
PCT/US2020/026686 WO2020206330A1 (en) 2019-04-05 2020-04-03 Heavy chain antibodies binding to psma

Publications (1)

Publication Number Publication Date
CO2021013279A2 true CO2021013279A2 (es) 2022-01-17

Family

ID=70476405

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0013279A CO2021013279A2 (es) 2019-04-05 2021-10-04 Anticuerpos de cadena pesada que se unen al psma

Country Status (17)

Country Link
US (2) US20220195068A1 (es)
EP (1) EP3947470A1 (es)
JP (1) JP2022526595A (es)
KR (1) KR20210149076A (es)
AU (1) AU2020252556A1 (es)
BR (1) BR112021019334A2 (es)
CA (1) CA3133654A1 (es)
CL (1) CL2021002586A1 (es)
CO (1) CO2021013279A2 (es)
CR (1) CR20210500A (es)
EA (1) EA202192736A1 (es)
IL (1) IL286398A (es)
JO (1) JOP20210253A1 (es)
MX (1) MX2021012205A (es)
PE (1) PE20220142A1 (es)
SG (1) SG11202111027WA (es)
WO (1) WO2020206330A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017281034B2 (en) 2016-06-21 2024-03-14 Teneobio, Inc. CD3 binding antibodies
KR102507537B1 (ko) 2016-09-14 2023-03-08 테네오원, 인코포레이티드 Cd3 결합 항체
KR20200018498A (ko) 2017-06-20 2020-02-19 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
EP3642236A1 (en) 2017-06-20 2020-04-29 TeneoOne, Inc. Anti-bcma heavy chain-only antibodies
AU2018392088A1 (en) 2017-12-22 2020-08-13 Teneobio, Inc. Heavy chain antibodies binding to CD22
MX2021015337A (es) 2019-06-14 2022-01-18 Teneobio Inc Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3.
IL297601A (en) 2020-04-29 2022-12-01 Teneobio Inc Multispecific heavy chain antibodies with modified heavy chain constant regions
KR20230137393A (ko) * 2021-01-28 2023-10-04 얀센 바이오테크 인코포레이티드 Psma 결합 단백질 및 이의 용도
JP2024507540A (ja) * 2021-02-25 2024-02-20 テネオバイオ， インコーポレイテッド 抗ｐｓｍａ抗体及びｃａｒ－ｔ構造
KR20230171952A (ko) * 2021-04-16 2023-12-21 테네오바이오, 인코포레이티드 항-cd20 항체 및 car-t 구조
WO2022232376A1 (en) 2021-04-29 2022-11-03 Amgen Inc. Methods for reducing low molecular weight species of recombinantly-produced proteins
WO2023183231A1 (en) 2022-03-21 2023-09-28 Amgen Inc. Combination therapy methods with t-cell engaging molecules for treatment of prostate cancer

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE69233254T2 (de) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
DE69731289D1 (de) 1996-03-18 2004-11-25 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
CA2499300A1 (en) 2002-10-31 2004-05-21 Genentech, Inc. Methods and compositions for increasing antibody production
AU2004205684A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
EP1864998B2 (en) 2004-07-22 2022-06-22 Erasmus University Medical Center Rotterdam Binding molecules
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
EP2406284B9 (en) 2009-03-10 2017-03-01 Biogen MA Inc. Anti-bcma antibodies
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
JP6688551B2 (ja) * 2015-05-21 2020-04-28 ハープーン セラピューティクス，インク． 三重特異性結合タンパク質と使用方法
CN108473590B (zh) * 2016-01-12 2023-04-14 克雷森多生物制剂有限公司 治疗分子
AU2017281034B2 (en) 2016-06-21 2024-03-14 Teneobio, Inc. CD3 binding antibodies
KR102507537B1 (ko) 2016-09-14 2023-03-08 테네오원, 인코포레이티드 Cd3 결합 항체
GB201711068D0 (en) * 2017-07-10 2017-08-23 Crescendo Biologics Ltd Therapeutic molecules binding PSMA

Also Published As

Publication number Publication date
CL2021002586A1 (es) 2022-05-06
CR20210500A (es) 2021-11-05
IL286398A (en) 2021-10-31
CA3133654A1 (en) 2020-10-08
EP3947470A1 (en) 2022-02-09
US20230242668A1 (en) 2023-08-03
PE20220142A1 (es) 2022-01-27
EA202192736A1 (ru) 2022-01-27
CN113710707A (zh) 2021-11-26
BR112021019334A2 (pt) 2021-12-07
US20220195068A1 (en) 2022-06-23
AU2020252556A1 (en) 2021-10-21
JP2022526595A (ja) 2022-05-25
WO2020206330A1 (en) 2020-10-08
JOP20210253A1 (ar) 2023-01-30
KR20210149076A (ko) 2021-12-08
MX2021012205A (es) 2022-02-21
SG11202111027WA (en) 2021-11-29

Similar Documents

Publication Publication Date Title
CL2021002586A1 (es) Anticuerpos de cadena pesada que se unen al psma
CL2017002401A1 (es) Anticuerpos contra icos
BR112019012354A2 (pt) anticorpos apenas de cadeia pesada anti-bcma
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CO2021016907A2 (es) Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
PE20180672A1 (es) Anticuerpos anti-ctla-4 y metodos de uso de los mismos
CO2020008925A2 (es) Anticuerpos de cadena pesada que se unen a cd22
MX2020006668A (es) Anticuerpos para lilrb2.
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
DOP2020000020A (es) Anticuerpos anti-cd137
CO2020010277A2 (es) Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl
DOP2017000236A (es) Neutralización del virus chikungunya mediada por anticuerpos
CU20160133A7 (es) Anticuerpos anti-mcam y métodos de uso asociados
CO2021002954A2 (es) Anticuerpos anti-αvβ8 y composiciones y usos de los mismos
CL2022002963A1 (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
CR20170020A (es) Variantes de proteínas de unión al factor h y métodos de uso de estas
NI201900034A (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y uso de los mismos
CO2023006790A2 (es) Anticuerpos de cadena pesada que se unen al receptor de folato alfa
CO2023000808A2 (es) Unión de anticuerpos multiespecíficos a bcma
CL2021003563A1 (es) Anticuerpos para la unión a psma
CL2023003073A1 (es) Anticuerpos anti-cd20 y estructuras car-t
BR112018070603A2 (pt) formulações líquidas de fosfaplatina
CL2023002284A1 (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
AR110942A1 (es) Composiciones y métodos para terapias de células t con car